CalciMedica Insider Filing: Glicklich Receives 39k Options, Minimal Dilution
Rhea-AI Filing Summary
CalciMedica, Inc. (CALC) – Form 4 insider filing
Director Alan Glicklich reported the award of four separate stock-option grants on 24 June 2025 under the company’s Amended 2023 Equity Incentive Plan, which was approved by shareholders the same day. All transactions are coded “A” (acquired) and represent incentive compensation rather than open-market buying.
- 10,000 options at an exercise price of $1.53; 1/12th vests monthly over one year from 26 Mar 2025; expires 22 Apr 2035.
- 4,166 options at $1.53; immediately exercisable; expires 22 Apr 2035.
- 15,000 options at $1.53; 1/9th vests monthly over one year from 1 Apr 2025; expires 22 Apr 2035.
- 10,000 options at $1.65; 1/12th vests monthly over one year beginning 24 Jun 2025 (or fully vested by the 2026 AGM); expires 23 Jun 2035.
Following these grants, Glicklich beneficially owns 39,166 derivative securities (options) directly. No common shares were sold or purchased, and no indirect ownership is reported. Because the options are priced near recent market levels and include standard vesting schedules, the filing is primarily routine compensation disclosure with minimal immediate balance-sheet impact but adds modest future dilution potential.
Positive
- Director received 39,166 stock options, indicating continued engagement and potential alignment with shareholder interests through equity-based compensation.
- Shareholder approval of the Amended 2023 Equity Incentive Plan demonstrates transparent corporate governance.
Negative
- Future dilution risk exists if all options are eventually exercised, albeit currently immaterial.
- No open-market share purchase was reported, so the filing does not signal direct insider confidence in current valuation.
Insights
TL;DR: Routine director option grants; 39,166 options added at $1.53–$1.65, no cash outlay or open-market buying; limited near-term impact.
The filing shows standard equity compensation rather than insider conviction buying. Exercise prices slightly above $1.53 suggest alignment with recent trading ranges, so value is contingent on future price appreciation. Total grants equal roughly 0.2–0.3 % of a 20 million-share float (exact share count not provided), implying immaterial dilution. From a valuation standpoint, no earnings or operational data accompany the filing, so investors should treat this as neutral information.
TL;DR: Shareholder-approved plan delivered four option tranches; governance process appears compliant; impact predominantly neutral.
The board granted options subject to prior shareholder approval of the Amended 2023 EIP, indicating adherence to best-practice oversight. Vesting schedules (monthly installments and one immediately exercisable portion) create retention incentives while limiting windfall risks. No 10b5-1 plan is referenced for these grants, but Rule 10b5-1 checkbox remains unticked, consistent with compensation-based awards. Overall, the action reflects ordinary director remuneration and poses negligible governance concerns.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
| Grant/Award | Director Stock Option (Right to Buy) | 4,166 | $0.00 | -- |
| Grant/Award | Director Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Grant/Award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
Footnotes (1)
- The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025. Immediately exercisable. 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders.
